Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.62 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525204 | 1.00 | LRRK2 (0.62) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6525539 | 0.92 | NOS1 (0.51) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6525541 | 0.92 | NOS1 (0.51) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6525507 | 0.85 | RPS6KA3 (0.54) | PDGFRB | |
| SCHEMBL6531204 | 0.85 | MEN1 (0.52) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3721457 | 0.85 | APP (0.58) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3711780 | 0.85 | PLK4 (0.62) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6526040 | 0.85 | RPS6KA3 (0.54) | PDGFRB | |
| SCHEMBL3711781 | 0.85 | PLK4 (0.62) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3721460 | 0.85 | APP (0.58) | LRRK2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | LRRK2 254/4885PSEN1 3988/4885PSEN2 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.